Purpose: To quantify metamorphopsia with a novel objective method in patients with epiretinal membrane (ERM) and to compare the relationships among metamorphopsia scores, spectral-domain optical coherence tomography (OCT) findings, and multifocal electroretinogram (mfERG) results.
Methods: This study included 52 eyes of 52 patients with idiopathic ERM who underwent comprehensive ophthalmologic examinations, including measurement of best-corrected visual acuity (BCVA), OCT, and mfERG. The degree of metamorphopsia was quantified using MonPack One® (Metrovision, Perenchies, France). On the topographic map of the early treatment diabetic retinopathy (ETDRS) grid, retinal thickness in the central, superior, inferior, nasal, and temporal subfields were measured, and metamorphopsia scores for each corresponding subfield were also obtained. The amplitudes and implicit times of mERG were elicited from each subfield. Then, the correlations among metamorphopsia scores, OCT findings, and mfERG responses were analyzed.
Results: The mean age of the patients was 65.3 ± 18.5 y, and the average metamorphopsia score of the individual subfields was 2.03 ± 1.18. Initial BCVA was 0.50 ± 0.12 logMAR, but there was no significant correlation between metamorphopsia scores and BCVA. The metamorphopsia scores from the central subfields showed significant correlations with central retinal thickness (CRT) (p = 0.001). The mean metamorphopsia scores in the central subfield showed a significant relationship with the mean N1 and P1 amplitudes (p = 0.001, p = 0.048, respectively), while no relationship was observed between metamorphopsia scores and mfERG amplitudes in other subfields.
Conclusions: The degree of metamorphopsia in patients with ERM could be objectively quantified in each subfield using a novel metamorphopsia test. The metamorphopsia scores were significantly correlated with retinal thickness, especially at the central subfields, and the scores in the central subfields were significantly correlated with the N1 and P1 amplitudes of mfERG. Thus, the metamorphopsia test can be a useful method to evaluate metamorphopsia symptoms for patients with ERM.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116302 | PMC |
http://dx.doi.org/10.1007/s10633-020-09803-x | DOI Listing |
Alzheimers Dement
December 2024
Yonsei University, Wonju, Gangwon-do, Korea, Republic of (South).
Background: Dementia and visual impairment are both associated with reduced mobility and impaired functioning in activities of daily living (ADL) and instrumental activities of daily living (IADL). Cognitive deficits in older adults have more difficulties in performing daily tasks, increase the risk of fear of participation and may lead to injury (e.g.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
École d'optométrie, Université de Montréal, Montréal, QC, Canada.
Background: Occupational therapists (OTs) play a crucial role in rehabilitation, aiming to improve the lives of individuals with sensory impairment and an increased risk of cognitive decline. Despite being responsible for cognitive screenings on occasion, they have expressed limited confidence in performing these with their clients with visual and/or hearing impairments (VI/HI). To improve this situation, OTs should gain expertise in collaborative sensory rehabilitation.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Texas, Austin, TX, USA.
Background: Primary progressive aphasia (PPA) is a language-based dementia linked with underlying Alzheimer's disease (AD) or frontotemporal dementia. Clinicians often report difficulty differentiating between the logopenic (lv) and nonfluent/agrammatic (nfv) subtypes, as both variants present with disruptions to "fluency" yet for different underlying reasons. In English, acoustic and linguistic markers from connected speech samples have shown promise in machine learning (ML)-based differentiation of nfv from lv.
View Article and Find Full Text PDFDiagnostics (Basel)
December 2024
Podoactiva Research & Development Department, Biomechanical Unit, Parque Tecnológico Walqa, Ctra. N330a Km 566, 22197 Cuarte, Spain.
: Sarcopenia and cognitive decline (CD) are prevalent in aging populations, impacting functionality and quality of life. The early detection of these diseases is challenging, often relying on in-person screening, which is difficult to implement regularly. This study aims to develop artificial intelligence algorithms based on gait analysis, integrating sensor and computer vision (CV) data, to detect sarcopenia and CD.
View Article and Find Full Text PDFJ Manag Care Spec Pharm
January 2025
Humana Healthcare Research, Inc., Louisville, KY.
Background: Geographic atrophy (GA) is a form of advanced age-related macular degeneration (AMD) that can cause irreversible vision impairment and is responsible for approximately 20% of legal blindness in the United States. There is limited real-world evidence assessing health outcomes and health care resource use (HCRU) among individuals with GA.
Objective: To examine the progression from GA without subfoveal involvement (SFI) to GA with SFI, progression to irreversible blindness, and HCRU among older individuals with GA enrolled in Medicare Advantage Prescription Drug (MAPD) plans.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!